Adults aged 18 to 49 years at increased risk for RSV-associated lower respiratory tract disease are now eligible for the Arexvy vaccine.
Imagine you're about to give a presentation to a room full of people.
In 2024, doctors and parents scrambled to find an affordable asthma inhaler after drugmaker GSK pulled the popular Flovent off the market. A senator launched an investigation to find out what happened ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results